archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • bioCSL
    formerly a part of CSL Biotherapies manufactures and markets biological products for human use in licenses and markets vaccines and prescription pharmaceuticals to treat a range of human medical conditions as well as manufactures and markets in vitro diagnostic products Headquartered in Australia bioCSL also has operations based in New Zealand and the USA Vaccines manufactured by CSL are used in global markets The international demand for CSL s influenza vaccine continues to grow as the benefits of protection from this life threatening disease are more widely recognised around the world bioCSL Australia For information about the vaccines anti venoms in licensed pharmaceuticals and immunohaematology products diagnostic reagents that bioCSL distributes in Australia please visit the bioCSL Australia website If you are interested in new partnerships regarding in licensed pharmaceuticals please visit the bioCSL Australia website for more information CSL direct provides a convenient ordering portal for bioCSL products and Vaccines visit the CSL Direct website If you would like more information about CSL direct please contact CSL customer service on 1800 008 275 bioCSL New Zealand For information about prescription medicines and vaccines that bioCSL distributes in New Zealand visit the bioCSL New Zealand website bioCSL United States For

    Original URL path: http://www.csl.com.au/csl-biotherapies.htm (2014-01-05)
    Open archived version from archive

  • CSL Ltd products provide treatment of serious medical conditions
    Mexico Netherlands Nordic Spain Switzerland UK USA CSL Plasma US CSL Plasma Germany About CSL Our Businesses Our Products Product Finder Complete Product List Research and Development Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home Our Products Product

    Original URL path: http://www.csl.com.au/products/product-finder.htm (2014-01-05)
    Open archived version from archive

  • Complete Product List
    Screening Cells Reagent Red Blood Cells Used in detecting unexpected alloantibodies other than anti D bioCSL Immunohaematology Abtectcell III 3 Reagent Red Blood Cells Used to detect unexpected alloantibodies using tube technique bioCSL Immunohaematology AHG Anti IgG Anti Human Globulin Reagent Used for detection of clinically relevant IgG subtypes bioCSL Immunohaematology AHG Control Cells 3 Reagent Red Blood Cells Used for the confirmation of antiglobulin activity bioCSL Immunohaematology Anti A 1 ABO Reagent Used to detect Group A 1 red cells bioCSL Immunohaematology Anti Fy a Phenotyping Reagent Used to detect the presence of the Fy a antigen on human red cells bioCSL Immunohaematology Anti Fy b Phenotyping Reagent Used to detect the presence of the Fy b antigen on human red cells bioCSL Immunohaematology Anti k Cellano Phenotyping Reagent Used to detect the presence of the k Cellano antigen on human red cells bioCSL Immunohaematology Anti Kp a Phenotyping Reagent Used to detect the presence of the Kp a antigen on human red cells bioCSL Immunohaematology Bovine Albumin 30 Solution Supplementary Reagent Used to enhance the agglutination of red cells in antibody detection tests bioCSL Immunohaematology Celpresol Supplementary Reagent Designed for the preservation suspension and resuscitation of human red blood cells bioCSL Immunohaematology Celpresol LISS Supplementary Reagent Designed for the preservation suspension and resuscitation of human red blood cells bioCSL Immunohaematology Controcell 2 EU and US only Reagent Red Blood Cells Designed to control standardise and validate all routine immunohaematology tests bioCSL Immunohaematology Controcell 4 EU and US only Reagent Red Blood Cells Designed to control standardise and validate all routine immunohaematology tests bioCSL Immunohaematology Cord Cells 3 Reagent Red Blood Cells Used for confirming the presence of anti I in an antibody identification procedure bioCSL Immunohaematology Epiclone AHG Poly Anti Human Globulin Reagent Used for detection of clinically relevant IgG subtypes bioCSL Immunohaematology Epiclone Anti A ABO Reagent Used to detect the presence of the A antigen on human red cells bioCSL Immunohaematology Epiclone Anti A B ABO Reagent Used to detect the presence of the A and B antigens on human red cells bioCSL Immunohaematology Epiclone Anti B ABO Reagent Used to detect the presence of the B antigen on human red cells bioCSL Immunohaematology Epiclone Anti C Phenotyping Reagent Used to detect the presence of the C antigen on human red cells bioCSL Immunohaematology Epiclone Anti c Phenotyping Reagent Used to detect the presence of the c antigen on human red cells bioCSL Immunohaematology Epiclone Anti C3d Anti Human Globulin Reagent Used to only detect the clinically relevant complement components in relation to Anti C3d bioCSL Immunohaematology Epiclone Anti C w Phenotyping Reagent Used to detect the presence of the C w antigen on human red cells bioCSL Immunohaematology Epiclone Anti DCE Phenotyping Reagent Used to detect the presence of the D C and E antigens on human red cells bioCSL Immunohaematology Epiclone Anti E Phenotyping Reagent Used to detect the presence of the E antigen on human red cells bioCSL Immunohaematology Epiclone Anti e Phenotyping Reagent Used to detect the presence of the e antigen on human red cells bioCSL Immunohaematology Epiclone Anti Jk a Phenotyping Reagent Used to detect the presence of the Jk a antigen on human red cells bioCSL Immunohaematology Epiclone Anti Jk b Phenotyping Reagent Used to detect the presence of the Jk b antigen on human red cells bioCSL Immunohaematology Epiclone Anti K Kell Phenotyping Reagent Used to detect the presence of the K antigen on human red cells bioCSL Immunohaematology Epiclone Anti Le a Phenotyping Reagent Used to detect the presence of the Le a antigen on human red cells bioCSL Immunohaematology Epiclone Anti Le b Phenotyping Reagent Used to detect the presence of the Le b antigen on human red cells bioCSL Immunohaematology Epiclone Anti M Phenotyping Reagent Used to detect the presence of the M antigen on human red cells bioCSL Immunohaematology Epiclone Anti N Phenotyping Reagent Used to detect the presence of the N antigen on human red cells bioCSL Immunohaematology Epiclone Anti P1 Phenotyping Reagent Used to detect the presence of the P1 antigen on red blood cells bioCSL Immunohaematology Epiclone Anti s Phenotyping Reagent Used to detect the presence of the s antigen on human red cells bioCSL Immunohaematology Epiclone Anti S Phenotyping Reagent Used to detect the presence of the S antigen on human red cells bioCSL Immunohaematology Epiclone 2 Anti D IgM RhD Reagent Used to detect the presence of RhD positive human red cells bioCSL Immunohaematology Epiclone 2 Anti D IgM IgG RhD Reagent Designed for routine RhD typing of human red cells bioCSL Immunohaematology Papain Solution Supplementary Reagent Used to treat human red cells in immunohaematological testing bioCSL Immunohaematology Phenocell 0 8 Reagent Red Blood Cells Used in identification of unexpected alloantibodies using Column Agglutination Technology CAT Systems bioCSL Immunohaematology Phenocell 3 Reagent Red Blood Cells Used in identification of unexpected alloantibodies using tube technique bioCSL Immunohaematology Phenocell 0 8 C Panel Reagent Red Blood Cells Used in identification of unexpected rare and unusual alloantibodies using Column Agglutination Technology CAT Systems bioCSL Immunohaematology Phenocell 3 C Panel Reagent Red Blood Cells Used in identification of unexpected rare and unusual alloantibodies using tube technique bioCSL Immunohaematology RAM Supplementary Reagent Designed for use in tube technique antibody screening identification and cross matching bioCSL Immunohaematology RAMPEG Supplementary Reagent Designed for use in tube technique antibody screening and identification bioCSL Immunohaematology Revercell 0 8 Reagent Red Blood Cells Used to detect ABO blood group antibodies using Column Agglutination Technology CAT Systems bioCSL Immunohaematology Revercell 15 Reagent Red Blood Cells Used to detect ABO blood group antibodies using tile techniques bioCSL Immunohaematology Revercell 3 Reagent Red Blood Cells Used to detect ABO blood group antibodies using tube techniques bioCSL Immunohaematology Securacell Reagent Red Blood Cells Designed to control standardise and validate all routine immunohaematology tests bioCSL Immunohaematology Securacell Light Reagent Red Blood Cells Designed to control standardise and validate all routine immunohaematology tests bioCSL Immunohaematology Snake Venom Detection Kit SVDK Snake Venom Detection Designed to

    Original URL path: http://www.csl.com.au/products/complete-product-list.htm (2014-01-05)
    Open archived version from archive

  • CSL R&D Portfolio - Product Pipeline and Innovation
    Corporate Responsibility Careers Newsroom Contact CSL Home Research and Development Product Pipeline Global R D Product Pipeline Our product portfolio focuses on innovation in new products improved products and manufacturing expertise thereby ensuring our continued growth Our balanced research and development portfolio is divided into three categories life cycle management market development and new product development Lifecycle management ensures continuous product improvement by maintaining and increasing competitiveness within our existing product range Market development brings therapies to new markets and new indications by maximizing market opportunities for our existing product range New product development creates specialty therapies to treat life threatening diseases It ensures long term growth primarily through projects aligned with our current marketing channels For a brief description of any of the products listed in our pipeline please visit the Product Pipeline Description page Research Pre Clinical Clinical Development Registration Post Launch Life Cycle Management Immunoglobulins Haemophilia Specialty Products Influenza Vaccine Market Development Fibrinogen New Indications PCC New Indications Hizentra CIDP Fibrinogen Aortic EU Zemaira EU Berinert SC Privigen CIDP Hizentra biweekly Hizentra Japan Voncento EU Zemaira EU Kcentra US Bleeding New Product Development Novel Plasma Proteins Rec Coagulation Factors rvWF FP Partnered Vaccine Programs P gingivalis POD

    Original URL path: http://www.csl.com.au/research-development/product-pipeline.htm (2014-01-05)
    Open archived version from archive

  • Highlights for CSL's Research and Development
    e g warfarin therapy in adult patients with acute major bleeding Approval was granted following completion of a pivotal clinical trial which showed that Kcentra met all efficacy and safety endpoints including the endpoints of hemostatic efficacy and International Normalized Ratio INR reduction compared with plasma the most widely used agent for warfarin reversal in the United States Kcentra restored the decreased vitamin K dependent clotting factors significantly faster than plasma in patients on warfarin and provides another option to medical professionals for stopping major bleeding in patients for whom plasma may not be optimal In December 2013 the US FDA approved an expanded indication for Kcentra This new indication allows its use during urgent surgery invasive procedures On 12 October 2009 the US FDA granted marketing approval for Berinert C1 Esterase Inhibitor for the treatment of acute abdominal or facial attacks associated with hereditary angioderma HAE a rare and serious genetic disorder Berinert the first and only therapy approved for this indication in the US It is now licensed in 31 countries worldwide On 25 August 2011 CSL Behring announced that European health authorities had approved self administration of Berinert and in January 2012 the US FDA also approved a label expansion for self administration of Berinert A Phase II study has also recently been completed evaluating a convenient volume reduced subcutaneous formulation of Berinert in patients with HAE A Phase III study commenced in late 2013 Haemophilia Products CSL scientists are committed to expanding the coagulation therapies portfolio through development of recombinant coagulation factor medicines to treat haemophilia and other coagulation disorders Recombinant forms of factors IX and Vlla are in development utilising albumin fusion technology which extends the half life of the circulating molecules If successful this should result in a marked reduction in the frequency of administration and would significantly increase convenience for patients CSL is also developing a unique single chain recombinant factor VIII rVIII SingleChain for treatment of haemophilia A On 2 February 2012 CSL announced results of a Phase I study evaluating recombinant fusion protein linking coagulation factor IX with albumin rIX FP in patients with severe haemophilia B Results of the study showed the rIX FP was well tolerated with no serious adverse events no presence of inhibitors to factor IX or antibodies to rIX FP were reported Terminal half life a measure of how long the drug lasts in the body was more than five times longer in comparison to values associated with current recombinant FIX therapy A pivotal Phase II III adult study was completed in 2013 Also in January 2013 the first patient was enrolled in a pivotal Phase III paediatric study to evaluate the safety efficacy and pharmacokinetics of rIX FP in previously treated children with haemophilia B On 16 February 2012 CSL announced that it had been granted Orphan Drug Designation by the US Food and Drug Administration for its novel recombinant fusion protein linking activated coagulation factor VIIa with recombinant albumin rVIIa FP The Orphan Drug

    Original URL path: http://www.csl.com.au/research-development/recent-highlights.htm (2014-01-05)
    Open archived version from archive

  • CSL's investment in research and development
    R D CSL is investing in the development of new protein based medicines for treating serious human diseases as an important avenue to future growth We have increased our investments significantly over recent years In 2012 13 we invested USD 427 million in our R D programs and this will continue to increase in 2013 2014 R D investment remains an important avenue to future growth for CSL We now

    Original URL path: http://www.csl.com.au/research-development/investments.htm (2014-01-05)
    Open archived version from archive

  • CSL's core capabilities in Research and Development
    has launched a program to develop robust recombinant candidates With extensive experience in producing large scale polyclonal plasma derived immunoglobulins CSL is developing expertise and building facilities to support the production and testing of recombinant proteins particularly monoclonal antibodies MAbs to treat cancer and inflammation CSL has developed a portfolio of MAbs in various stages of development targeted against multiple targets CSL has continued to strengthen its capabilities in later stage clinical and product development of recombinant products This has been achieved through hiring world class scientific and medical leaders for key projects and ensuring access to R D manufacturing capacity through relationships with contract manufacturers and investment in CSL s own facilities Developing our capability to take recombinant products into the clinic and ultimately to patients construction is now complete of a new state of the art biotechnology manufacturing facility at our Broadmeadows site in Melbourne Vaccines Licensing Significant R D activities support CSL s Influenza vaccine business in providing services to production and the regulatory and clinical capability required to support registrations in international markets We support bioCSL in providing manufacturing seed development and process development for each new influenza strain to be incorporated annually into the southern and northern hemisphere seasonal vaccines As the only vaccine manufacturer in the southern hemisphere we also play a key role in supporting seed development for newly circulating influenza strains antigen reagent development and vaccine supply to the global influenza network including the WHO regulatory authorities testing laboratories and other companies CSL also have significant capabilities relating to the development and supply of pandemic influenza vaccines as well as understanding the biology undrelying the disease itself ISCOMATRIX Adjuvant Adjuvants are used to enhance or modify the immune response to antigens in vaccines ISCOMATRIX adjuvant has antigen delivery as well as immunomodulatory

    Original URL path: http://www.csl.com.au/research-development/core-capabilities.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited conducts Research & Development at locations worldwide
    Denmark France Germany Italy Japan Mexico Netherlands Nordic Spain Switzerland UK USA CSL Plasma US CSL Plasma Germany About CSL Our Businesses Our Products Research and Development R D Highlights Investment in R D Core Capabilities Global R D Network Product Pipeline Clinical Trials Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home Research and Development Global R D Network Global R D Network CSL s research and development

    Original URL path: http://www.csl.com.au/research-development/global-research-development-network.htm (2014-01-05)
    Open archived version from archive